What is LSTA's current stock price?

LSTA (Lisata Therapeutics, Inc.) is currently trading at $3.14 with a market cap of $28.6M.

What sector is Lisata Therapeutics, Inc. in?

Lisata Therapeutics, Inc. (LSTA) operates in the Healthcare sector, specifically in the Biotechnology industry.

InvestLog

LSTA Lisata Therapeutics, Inc.

Healthcare

$3.14+0.00%ClosedMarket Cap: $28.6M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

2.59

P/S

168.20

EV/EBITDA

-0.92

DCF Value

$1.92

FCF Yield

-47.8%

Div Yield

0.0%

Margins & Returns

Gross Margin

98.8%

Operating Margin

-10178.2%

Net Margin

-9618.2%

ROE

-101.9%

ROA

-116.3%

ROIC

-157.3%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-4.5M	$—
Q4 null	$100.0K	$-3.0M	$—
FY null	$170.0K	$-16.6M	$—
Q3 null	$0.00	$-4.2M	$—

Analyst Ratings

View All

Consensus

Hold

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

1 Strong Buy0 Buy2 Hold0 Sell0 Strong Sell

HC Wainwright & Co.Neutral

2026-05-15

Brookline CapitalHold

2026-01-21

HC Wainwright & Co.Buy

2025-08-21

Brookline CapitalBuy

2025-07-15

Trading Activity

Insider Trades

View All

Nisco Jamesofficer: SVP, Fin/Treas, Chief Actg Off

SellTue Jan 13

Nisco Jamesofficer: SVP, Fin/Treas, Chief Actg Off

SellTue Jan 13

Nisco Jamesofficer: SVP, Fin/Treas, Chief Actg Off

SellTue Jan 13

Mazzo David Jdirector, officer: President & CEO

SellTue Jan 13

Mazzo David Jdirector, officer: President & CEO

SellTue Jan 13

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.81

Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Peers